The U.S. Food and Drug Administration’s approval of Viz.ai’s hypertrophic cardiomyopathy establishes a new category for cardiovascular machine learning-based notification software.
WHY IT MATTERS
Viz.ai, a disease detection and intelligent care coordination company, said in its announcement…
Source: Healthcareitnews.com and Read More
StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results
A strong quarterly earnings report that beat analyst expectations, growth that extended into core pharma and biotech tools, plus improved investor guidance on revenue, operating
